Breast Cancer
Conditions
Interventions
SLNB+WLNB group:None
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Female patients with pathologically confirmed primary invasive breast cancer by core needle biopsy; 2.Aged >= 18 years; 3.No palpable axillary lymph nodes on clinical examination; ultrasound demonstrates 1 or 2 suspicious axillary lymph nodes on the ipsilateral side (meeting malignant features: cortical thickness > 3 mm, hypoechogenicity, etc.), with at least 1 node confirmed metastatic by biopsy; patients with = 3 suspicious nodes are excluded; 4.Maximum diameter of breast tumor = 5 cm (T1–2); 5.No distant metastasis detected on staging examinations; 6.No prior neoadjuvant therapy; 7.The attending physician has performed combined sentinel lymph node biopsy (SLNB) and wire-guided lymph node biopsy in accordance with standard clinical protocols; 8.Patients with 1 to 2 positive lymph nodes on combined lymph node biopsy who received breast-conserving surgery (BCS) and were exempt from axillary lymph node dissection (ALND); or patients with 1 to 2 positive lymph nodes who underwent modified radical mastectomy (MRM); or patients with more than 2 positive lymph nodes who received axillary lymph node dissection (ALND), regardless of breast surgical approach (breast-conserving surgery or total mastectomy); 9.The patient voluntarily enrolled in this observational study and signed the informed consent form (ICF).
Exclusion criteria
Exclusion criteria: 1.Bilateral breast cancer; 2.Stage IV breast cancer; 3.Receipt of neoadjuvant therapy preoperatively; 4.History of previous ipsilateral axillary surgery (e.g., bromhidrosis surgery, lymph node biopsy) or axillary radiotherapy; 5.Concurrent other malignancies within the past 5 years, except cured squamous cell carcinoma of the skin, basal cell carcinoma, non-muscle invasive bladder cancer, carcinoma in situ of the cervix or breast, etc; 6.Pregnant or lactating women; 7.Severe cardiac or pulmonary dysfunction incompatible with surgery;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overall proportion of patients with total postoperative positive lymph nodes <= 2; | — |
Countries
China
Contacts
Public ContactJiwei Wang
Beijing Cancer Hospital
Outcome results
None listed